A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT04275518
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳The First Affilated Hospital of Ganzhou Medical University, Suzhou, Jiangsu, China
🇨🇳Guangzhou panyu central hospital, Guangzhou, Guangdong, China
APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- Drug: APG2575 400 mgDrug: APG2575 800 mgDrug: APG2575 600 mg
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04260217
- Locations
- 🇨🇳
Zhongshan Hospital of Fudan University, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital,College Of Medicine,Zhejiang University, Hangzhou, China
🇨🇳Beijing Chaoyang Hospital, Beijing, China
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Conditions
- Leukemia, Myeloid, ChronicMyeloid LeukemiaChronic Myeloid LeukemiaB Cell Precursor Type Acute LeukemiaPhiladelphia Positive Acute Lymphoblastic Leukemia
- Interventions
- Drug: Ascentage Pharma HQP1351 bioavailable inhibitor
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT04260022
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸City of Hope, Duarte, California, United States
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT04215809
- Locations
- 🇦🇺
Princess Alexandria Hospital, Brisbane, Queensland, Australia
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04210037
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04126707
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
- Conditions
- Chronic Myeloid Leukemia, Chronic Phase
- Interventions
- Drug: Imatinib, Dasatinib or Nilotinib
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT04126681
- Locations
- 🇨🇳
Nanfang hospital of southern medical university, Guangzhou, Guangdong, China
🇨🇳Union Hospital medical college Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine(hematology dept), Hangzhou, Zhejiang, China
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
- Conditions
- EGFR Positive Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT04001777
- Locations
- 🇨🇳
Henan Provincial people's Hospital, Zhengzhou, Henan, China
🇨🇳First Hospital of Jilin University, Chang chun, Jilin, China
🇨🇳Jilin Provincial Cancer Hospital, Changchun, Jilin, China
APG-2449 in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid CancerNon Small Cell Lung CancerEsophageal CancerOvarian CancerMalignant Pleural Mesothelioma
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT03917043
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
- Conditions
- Chronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT03913949
- Locations
- 🇨🇳
Henan Provincial Oncology Hospital, Zhengzhou, Henan, China
🇨🇳Anhui Procincial hospital, Hefei, Anhui, China
🇨🇳Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China